BEGIN:VCALENDAR
PRODID:NingEventWidget-v1
VERSION:2.0
METHOD:PUBLISH
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:19700308T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:19701101T020000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:2140535:Event:68807
DTSTAMP:20260606T033627Z
SUMMARY:Webinar on FDA New Drug Approval Process
DESCRIPTION:Overview: \nIn the calendar year 2015, the pharmaceutical
  industry witnessed the largest number of Food and Drug Administration
  (FDA) prescription drug approvals in the past decade. The FDA's Cente
 r for Drug Evaluation and Research played a valuable and key role in b
 ringing these drugs to market.\nWhy should you Attend: \nBy definitio
 n, drug development is the process of bringing a new pharmaceutical dr
 ug product to market once a lead compound has been identified through 
 the process of drug discovery. Although the drug approval process has 
 its rewards, sponsors, clinical investigators and regulatory professio
 nal need to understand the complete process, resources and guideline a
 vailable to assist them in all phases of clinical development.\nSpeake
 r Profile:\nHarold Thibodeaux is a medical research scientist with i
 n vivo pharmacological experiences in both academia and biopharmaceuti
 cal industry. During his prestigious career the focus of Mr. Thibodeau
 x’s research efforts has been on the efficacy of cardiovascular drug
 s most notably Hypertension, Myocardial Infarction, Focal Ischemia (St
 roke), Beyond Advair Pulmonary Research and topical antibiotics. Optim
 al therapeutic benefits were the goal in all of these projects but car
 diovascular safety to provide safer medicines to patients was a priori
 ty. Mr. Thibodeaux transitioned into the pharmaceutical industry when 
 he joined the Cardiovascular Department of Genentech in 1990, as a tec
 hnical lead with the Second Generation TPA Project Team. Mr. Thibodeau
 x is a graduate from the College of Charleston with a Bachelor of Scie
 nce Degree in biology and is a member of The Safety Pharmacology Socie
 ty. \n\nContact Detail:\nCompliance4All DBA NetZealous,Phone: +1-800-
 447-9407Email: support@compliance4All.comhttp://www.compliance4all.com
 /Event Link : http://bit.ly/New_Drug_Approval_Process\nLinkedIn Follo
 w us Twitter Follow usFacebook Like us\n\n\nFor more information visi
 t https://medtechiq.ning.com/events/webinar-on-fda-new-drug-approval-p
 rocess
DTSTART;TZID=America/New_York:20160412T100000
DTEND;TZID=America/New_York:20160412T113000
CATEGORIES:webinar
LOCATION:Online Event
WEBSITE:http://bit.ly/New_Drug_Approval_Process
URL:http://bit.ly/New_Drug_Approval_Process
CONTACT:18004479407
ORGANIZER;CN="Adam Fleming":https://medtechiq.ning.com/profile/Complia
 nce4all
ATTACH;FMTTYPE="image/jpeg":http://storage.ning.com/topology/rest/1.0/
 file/get/2562012284?profile=original
ATTENDEE;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;RSVP=TRUE;CN="Adam Fle
 ming":https://medtechiq.ning.com/profile/Compliance4all
END:VEVENT
END:VCALENDAR